Skip Navigation


JAC Advance Access originally published online on April 9, 2008
Journal of Antimicrobial Chemotherapy 2008 61(6):1187-1190; doi:10.1093/jac/dkn130
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
61/6/1187    most recent
dkn130v2
dkn130v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Vandekerckhove, L.
Right arrow Articles by Vogelaers, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vandekerckhove, L.
Right arrow Articles by Vogelaers, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Leading article

Maraviroc: integration of a new antiretroviral drug class into clinical practice

Linos Vandekerckhove1,*, Chris Verhofstede2 and Dirk Vogelaers1

1 AIDS Reference Centre, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium 2 AIDS Reference Laboratory, Ghent University, De Pintelaan 185, 9000 Ghent, Belgium

* Corresponding author. Tel: +32-93323398; Fax: +32-93325690; E-mail: linos.vandekerckhove{at}ugent.be

Maraviroc (Pfizer's UK-427857, Selzentry or Celsentri outside the US) is the first agent in the new class of oral HIV-1 entry inhibitors to acquire FDA and EMEA approval. It is expected that this drug will be effective only in a subpopulation of HIV-1-infected people, namely those harbouring only the R5 virus. The wide use of this drug is currently hampered by the lack of a readily available R5 virus only determination test (tropism test) and by insufficient scientific insight into the dynamics of R5 and X4 viruses during infection. We discuss the challenges associated with the currently available assay, as well as the potential role of alternative assays.

Keywords: tropism , chemokine receptor , co-receptor-blocker , V3 loop sequencing


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
L. Vandekerckhove, C. Verhofstede, and D. Vogelaers
Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients
J. Antimicrob. Chemother., June 1, 2009; 63(6): 1087 - 1096.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
N. Thakkar, V. Pirrone, S. Passic, W. Zhu, V. Kholodovych, W. Welsh, R. F. Rando, M. E. Labib, B. Wigdahl, and F. C. Krebs
Specific Interactions between the Viral Coreceptor CXCR4 and the Biguanide-Based Compound NB325 Mediate Inhibition of Human Immunodeficiency Virus Type 1 Infection
Antimicrob. Agents Chemother., February 1, 2009; 53(2): 631 - 638.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.